Please use this identifier to cite or link to this item: http://doi.org/10.25358/openscience-7267
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSprinzl, Martin F.-
dc.contributor.authorFeist, Christina-
dc.contributor.authorKoch, Sandra-
dc.contributor.authorKremer, Wolfgang Maximilian-
dc.contributor.authorLackner, Karl J.-
dc.contributor.authorWeinmann, Arndt-
dc.contributor.authorGalle, Peter R.-
dc.date.accessioned2022-06-30T10:26:08Z-
dc.date.available2022-06-30T10:26:08Z-
dc.date.issued2021-
dc.identifier.urihttps://openscience.ub.uni-mainz.de/handle/20.500.12030/7281-
dc.description.abstractBACKGROUND The PAGE-B score (Platelet Age GEnder–HBV) selects chronic hepatitis B (cHB) patients showing no relevant 5-year risk for hepatocellular carcinoma (HCC). We, therefore, explored potential cost reduction following the introduction of a PAGE-B tailored ultrasound screening in a single center cohort of cHB patients receiving stable antiviral therapy. METHODS cHB patients attending throughout the year 2018 were documented. Patients eligible for PAGE-B score were classified into high (≥18 points), intermediate (10–17 points) and low (≤9 points) HCC risk groups. Patients of the low HCC risk group could postpone HCC screening to reduce HCC screening expenses. Full costs for hepatic ultrasound were assessed. RESULTS Throughout the year cHB patients (n = 607) attended our clinic, which included PAGE-B eligible patients (n = 227, 37.4%) of whom n = 94 (15.8%) were allocated to the low HCC risk group. Sonographic HCC screening during a median exam time of 12.4 min (IQR 9.2–17.2) resulted in total costs of 22.82 Euro/exam. Additional opportunistic expenses caused by patient’s lost earnings or productivity were 15.6–17.5 €/exam and 26.7 €/exam, respectively. Following a PAGE-B tailored HCC screening at our institution annual full costs for cHB patients could be reduced by 15.51%, which equals a cost reduction by 1.91% for our total sonography unit. In comparison, 1.35% up to 7.65% of HBV-infected patients of Caucasian descent could postpone HCC screening according to population-based estimates from Germany. CONCLUSIONS PAGE-B risk score adapted screening for HCC is an efficient and cost neutral tool to reduce costs for sonography in Caucasian patients with chronic hepatitis B receiving antiviral treatment.en_GB
dc.language.isoengde
dc.rightsCC BY*
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.subject.ddc610 Medizinde_DE
dc.subject.ddc610 Medical sciencesen_GB
dc.titleCost evaluation of PAGE-B risk score guided HCC surveillance in patients with treated chronic hepatitis Ben_GB
dc.typeZeitschriftenaufsatzde
dc.identifier.doihttp://doi.org/10.25358/openscience-7267-
jgu.type.dinitypearticleen_GB
jgu.type.versionPublished versionde
jgu.type.resourceTextde
jgu.organisation.departmentFB 04 Medizinde
jgu.organisation.number2700-
jgu.organisation.nameJohannes Gutenberg-Universität Mainz-
jgu.rights.accessrightsopenAccess-
jgu.journal.titleBMC health services researchde
jgu.journal.volume21de
jgu.pages.alternative846de
jgu.publisher.year2021-
jgu.publisher.nameBioMed Centralde
jgu.publisher.placeLondonde
jgu.publisher.issn1472-6963de
jgu.organisation.placeMainz-
jgu.subject.ddccode610de
jgu.publisher.doi10.1186/s12913-021-06794-6de
jgu.organisation.rorhttps://ror.org/023b0x485-
Appears in collections:JGU-Publikationen

Files in This Item:
  File Description SizeFormat
Thumbnail
cost_evaluation_of_pageb_risk-20220630121855371.pdf786.96 kBAdobe PDFView/Open